Do you want to read an article? Please log in or register.
Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study of Hepatotoxicity, Completion, and Costs
Tuberculosis
RECOMMENDED
Related content
RECOMMENDED
Tuberculosis
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Infect Dis.
Campbell JR, Trajman A, Cook VJ, Johnston JC, Adjobimey M, Ruslami R, Eisenbeis L, Fregonese F, Valiquette C, Benedetti A, Menzies D
doi: 10.1016/S1473-3099(19)30575-4.
RECOMMENDED
TuberculosisFurther Publications
Effectiveness of pre-entry active tuberculosis and post-entry latent tuberculosis screening in new entrants to the UK: a retrospective, population-based cohort study
Lancet Infect Dis.
Berrocal-Almanza LC, Harris R, Lalor MK, Muzyamba MC, Were J, O'Connell AM, Mirza A, Kon OM, Lalvani A, Zenner D
doi: 10.1016/S1473-3099(19)30260-9.
Tuberculosis
Primary Care Screening and Treatment for Latent Tuberculosis Infection in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force
JAMA.
Kahwati LC, Feltner C, Halpern M, Woodell CL, Boland E, Amick HR, Weber RP, Jonas DE
doi: 10.1001/
RECOMMENDED
Tuberculosis
Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Glob Health.
Marx FM, Cohen T, Menzies NA, Salomon JA, Theron G, Yaesoubi R
doi: 10.1016/S2214-109X(20)30227-8.
Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis
Lancet Respir Med.
Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, Bang D, Bastos M, Benedetti A, Bonnet M, Cattamanchi A, Cegielski P, Chien JY, Cox H, Dedicoat M, Erkens C, Escalante P, Falzon D, Garcia-Prats AJ, Gegia M, Gillespie SH, Glynn JR, Goldberg S, Griffith D, Jacobson KR, Johnston JC, Jones-López EC, Khan A, Koh WJ, Kritski A, Lan ZY, Lee JH, Li PZ, Maciel EL, Galliez RM, Merle CSC, Munang M, Narendran G, Nguyen VN, Nunn A, Ohkado A, Park JS, Phillips PPJ, Ponnuraja C, Reves R, Romanowski K, Seung K, Schaaf HS, Skrahina A, Soolingen DV, Tabarsi P, Trajman A, Trieu L, Banurekha VV, Viiklepp P, Wang JY, Yoshiyama T, Menzies D
doi: 10.1016/S2213-2600
RECOMMENDED
Tuberculosis
Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med.
Hibma JE, Radtke KK, Dorman SE, Jindani A, Dooley KE, Weiner M, McIlleron HM, Savic RM
doi: 10.1164/rccm.201912-2489OC.
RECOMMENDED
Tuberculosis
Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
Lancet Infect Dis.
Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ
doi: 10.1016/S1473-3099(19)30307-X.
COMMENTED
Tuberculosis
Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study
Lancet Infect Dis.
Abubakar I, Drobniewski F, Southern J, Sitch AJ, Jackson C, Lipman M, Deeks JJ, Griffiths C, Bothamley G, Lynn W, Burgess H, Mann B, Imran A, Sridhar S, Tsou CY, Nikolayevskyy V, Rees-Roberts M, Whitworth H, Kon OM, Haldar P, Kunst H, Anderson S, Hayward A, Watson JM, Milburn H, Lalvani A; PREDICT Study Team
doi: 10.1016/
COMMENTED
Tuberculosis
Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
N Engl J Med.
Blanc FX, Badje AD, Bonnet M, Gabillard D, Messou E, Muzoora C, Samreth S, Nguyen BD, Borand L, Domergue A, Rapoud D, Natukunda N, Thai S, Juchet S, Eholié SP, Lawn SD, Domoua SK, Anglaret X, Laureillard D, STATIS ANRS 12290 Trial Team.
doi: 10.1056/NEJMoa1910708.